Neuropathy: The Crystal Ball for Cardiovascular Disease?
Year: 2010
Type: article
Abstract: Cardiovascular disease (CVD) is a major cause of death in patients with type 2 diabetes. Unclear, however, is the effect of intensive therapy in reducing the development of cardiovascular complications. The UK Prospective Diabetes Study (UKPDS), involving patients with newly diagnosed disease, showed a nonsignificant trend in the reduction of rates for myocardial infarction (MI) (1). However, data 10 years after cessation of the trial showed a 15 % reduction in the risk of MI for those in the original intensive therapy group (2). This benefit from early intensive therapy persisted despite the fact that the within-trial differences for A1C between the intensive and conventional therapy groups were lost within 1 year of completion of the trial. The sustained benefit from early aggressive treatment is referred to as the legacy effect or metabolic memory. The question of more intensive therapy and reduction in cardiovascular complications was addressed for people with type 2 diabetes of long duration in three other studies (i.e., the Action to
Source: Diabetes Care
DOI: 10.2337/dc10-0745
Authors: Aaron I. Vinik, Raelene E. Maser, Dan Ziegler
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W1974667696
